Next-Generation Oral SERD Approved for Breast Cancer | HappeningNow.news

Health · 3 views

Next-Generation Oral SERD Approved for Breast Cancer

(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative…

Source Summary Published 1h 44m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 3 Community interest
Brief read Under 1 min brief 28 words

Summary

(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated

Read original at MedPage Today

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page